MICHAEL A DAVIES to Neoplasms
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Neoplasms.
Connection Strength
0.556
-
Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e376.
Score: 0.099
-
Regulation, role, and targeting of Akt in cancer. J Clin Oncol. 2011 Dec 10; 29(35):4715-7.
Score: 0.062
-
Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother. 2006 Nov; 7(16):2243-61.
Score: 0.044
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.032
-
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.
Score: 0.032
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.029
-
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019 11 21; 7(1):319.
Score: 0.027
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.023
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.021
-
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
Score: 0.021
-
Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep. 2016 Jan 20; 6:19649.
Score: 0.021
-
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10.
Score: 0.020
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.020
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.020
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.020
-
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
Score: 0.019
-
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 03; 109(5):1085-92.
Score: 0.018
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
Score: 0.013
-
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002 Apr 04; 21(15):2357-64.
Score: 0.008
-
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
Score: 0.006